Evidence map›Paper›PMID 37299544›Full record

ArticleNutrients2023

Effects of Royal Jelly on Gut Dysbiosis and NAFLD in

Genki Kobayashi, Takuro Okamura, Saori Majima, Takafumi Senmaru, Hiroshi Okada, Emi Ushigome, Naoko Nakanishi, Yuichiro Nishimoto, Takuji Yamada, Hideto Okamoto and 4 more

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Review
  3. Royal jelly fermented byBiochemistry and biophysics reports · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Royal Jelly: Biological Action and Health Benefits.International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Genki KobayashiDepartment of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
Takuro OkamuraDepartment of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.ORCID 0000-0001-7269-1697
Saori MajimaDepartment of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
Takafumi SenmaruDepartment of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
Hiroshi OkadaDepartment of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.ORCID 0000-0002-1707-970X
Emi UshigomeDepartment of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.ORCID 0000-0003-1031-4380
Naoko NakanishiDepartment of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
Yuichiro NishimotoMetabologenomics Inc., Tsuruoka 997-0052, Japan.ORCID 0000-0002-4522-8717
Takuji YamadaMetabologenomics Inc., Tsuruoka 997-0052, Japan.
Hideto OkamotoInstitute for Health Science, R&D Department, Yamada Bee Company, Inc., Okayama 708-0393, Japan.ORCID 0000-0003-2904-4640
Nobuaki OkumuraInstitute for Health Science, R&D Department, Yamada Bee Company, Inc., Okayama 708-0393, Japan.ORCID 0000-0002-2997-7291
Ryoichi SasanoAiSTI SCIENCE Co., Ltd., Wakayama 640-0033, Japan.
Masahide HamaguchiDepartment of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.ORCID 0000-0002-8651-4445
Michiaki FukuiDepartment of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.ORCID 0000-0003-0903-1797
Kyoto Prefectural University of Medicine · JPInstitute for Biological Sciences · CATokyo Institute of Technology · JP

Funding

Yamada Bee Company, Inc. N/A
6 · The paper itself

Abstract

Royal jelly (RJ) is a naturally occurring substance synthesized by honeybees and has various health benefits. Herein, we focused on the medium-chain fatty acids (MCFAs) unique to RJ and evaluated their therapeutic efficacy in treating non-alcoholic fatty liver disease (NAFLD). We examined

Indexed as

Non-alcoholic Fatty Liver DiseaseAnimalsBeesDysbiosisFatty AcidsFibrosisInflammationMiceMice, Inbred StrainsRoyal JellyFatty AcidsRoyal Jellydysbiosisgut microbiotamedium-chain fatty acidsnon-alcoholic fatty liver diseaseroyal jelly

Identifiers

PMID37299544
PMCPMC10255852
OpenAlexW4378983065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.